<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Abacavir: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Abacavir: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Abacavir: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8993" href="/d/html/8993.html" rel="external">see "Abacavir: Drug information"</a> and <a class="drug drug_patient" data-topicid="12192" href="/d/html/12192.html" rel="external">see "Abacavir: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5696175"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Serious and sometimes fatal hypersensitivity reactions, with multiple organ involvement, have occurred with abacavir.</p>
<p style="text-indent:-2em;margin-left:2em;">Patients who carry the HLA-B*5701 allele are at a higher risk of a hypersensitivity reaction to abacavir; although, hypersensitivity reactions have occurred in patients who do not carry HLA-B*5701 allele.</p>
<p style="text-indent:-2em;margin-left:2em;">Abacavir is contraindicated in patients with a prior hypersensitivity reaction to abacavir and in HLA-B*5701–positive patients. All patients should be screened for the HLA-B*5701 allele prior to initiating therapy with abacavir or reinitiation of therapy with abacavir, unless patients have a previously documented HLA-B*5701 allele assessment. Discontinue abacavir immediately if a hypersensitivity reaction is suspected, regardless of HLA-B*5701 status and even when other diagnoses are possible.</p>
<p style="text-indent:-2em;margin-left:2em;">Following a hypersensitivity reaction to abacavir, never restart abacavir or any abacavir-containing product because more severe symptoms including death, can occur within hours. Similar severe reactions have also occurred rarely following the reintroduction of abacavir-containing products in patients who have no history of abacavir hypersensitivity.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F128749"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Ziagen</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52865509"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Abacavir;</li>
<li>MINT-Abacavir;</li>
<li>Ziagen</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1050695"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiretroviral Agent</span>;</li>
<li>
<span class="list-set-name">HIV Agents (Anti-HIV Agents)</span>;</li>
<li>
<span class="list-set-name">Nucleoside Reverse Transcriptase Inhibitor (NRTI)</span></li></ul></div>
<div class="block don drugH1Div" id="F58345377"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1ab19771-954c-4f98-99df-96287b52c01b">HIV-1 perinatal transmission, treatment or presumptive treatment for higher-risk patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 perinatal transmission, treatment or presumptive treatment for higher-risk patients: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Not currently recommended routinely as part of a presumptive HIV therapy regimen, but could be considered as an alternative to zidovudine if zidovudine is not available or not tolerated. Verify <i>HLA-B∗5701</i> negative prior to use. An appropriate combination regimen for presumptive therapy also serves as prophylaxis and should be continued for 2 to 6 weeks; the zidovudine component (or abacavir if replacing zidovudine) is recommended for a full 6 weeks even if the other 2 antiretrovirals are discontinued sooner; expert consultation is recommended. Treatment of documented HIV is lifelong. Dosing based on pharmacokinetic simulations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34883066','lexi-content-ref-HHS.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34883066','lexi-content-ref-HHS.4'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">GA ≥37 weeks:</p>
<p style="text-indent:-2em;margin-left:6em;">PNA &lt;4 weeks: Oral solution: Oral: 2 mg/kg/dose twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34883066','lexi-content-ref-HHS.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34883066','lexi-content-ref-HHS.4'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">PNA ≥4 weeks: Oral solution: Oral: 4 mg/kg/dose twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34883066','lexi-content-ref-HHS.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34883066','lexi-content-ref-HHS.4'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F128767"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="54b359d7-24b9-4b96-9d31-710e220dc129">HIV-1 infection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 infection, treatment:</b>
<b>Note:</b> Use in combination with other antiretroviral (ARV) agents; evaluate gene mutation and ARV resistance patterns (refer to https://www.iasusa.org/ and <a href="/external-redirect?target_url=https%3A%2F%2Fhivdb.stanford.edu%2F&amp;token=0UTGrOKwDz%2FcgdqCCfJ7%2BDRCcJYh1XL9dcrpjPtdJG0rff6lNL8ZXoJkPMlaspoX&amp;TOPIC_ID=13176" target="_blank">https://hivdb.stanford.edu/</a> for more information).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants &lt;3 months: Oral solution: Oral: 4 mg/kg/dose twice daily <b>Note: </b>Dosing is based on pharmacokinetic modeling (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34883066','lexi-content-ref-HHS.2','lexi-content-ref-HHS.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34883066','lexi-content-ref-HHS.2','lexi-content-ref-HHS.4'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥3 months, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Twice-daily dosing:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Weight-directed dosing: Oral solution: Oral: 8 mg/kg/dose twice daily; maximum dose: 300 mg/dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Weight-band dosing for patients ≥14 kg: Tablets (scored 300 mg tablets), oral solution:</p>
<p style="text-indent:-2em;margin-left:10em;">14 to &lt;20 kg: Oral: 150 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:10em;">20 to &lt;25 kg: Oral: 150 mg in the morning and 300 mg in the evening.</p>
<p style="text-indent:-2em;margin-left:10em;">≥25 kg: Oral: 300 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Once-daily dosing</i>: <b>Note:</b> For infants and young children beginning therapy with liquid formulations of abacavir, initiation with once-daily abacavir is not generally recommended. In clinically stable patients with undetectable viral load and stable CD4 counts receiving the liquid formulation twice daily, the daily dose can be changed from twice daily to once daily with liquid or tablet formulations. Initiation with once-daily dosing is recommended for children who can be treated with tablet formulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Weight-directed dosing: Oral solution: Oral: 16 mg/kg/dose once daily; maximum dose: 600 mg/dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Weight-band dosing for patients ≥14 kg: Tablets (scored 300 mg tablets), oral solution:</p>
<p style="text-indent:-2em;margin-left:10em;">14 to &lt;20 kg: Oral: 300 mg once daily.</p>
<p style="text-indent:-2em;margin-left:10em;">20 to &lt;25 kg: Oral: 450 mg once daily.</p>
<p style="text-indent:-2em;margin-left:10em;">≥25 kg: Oral: 600 mg once daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51011038"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, renal is a minor route of elimination.</p></div>
<div class="block dohp drugH1Div" id="F51011039"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">All patients:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment: Dosing adjustment is required; however, pediatric-specific recommendations are not available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate to severe hepatic impairment: Use is contraindicated.</p></div>
<div class="block doa drugH1Div" id="F128752"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8993" href="/d/html/8993.html" rel="external">see "Abacavir: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="54b359d7-24b9-4b96-9d31-710e220dc129">HIV-1 infection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 infection, treatment:</b>
<b>Oral:</b> 300 mg twice daily or 600 mg once daily in combination with other antiretroviral agents. <b>Note:</b> Abacavir, in combination with lamivudine and either efavirenz, raltegravir, boosted atazanavir, or boosted darunavir, should not be used in patients with pretreatment HIV RNA ≥100,000 copies/mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991497"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27624144','lexi-content-ref-25234519','lexi-content-ref-11528234','lexi-content-ref-18479171']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27624144','lexi-content-ref-25234519','lexi-content-ref-11528234','lexi-content-ref-18479171'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzable (~24%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11528234']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11528234'])">Ref</a></span>): No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25234519','lexi-content-ref-11528234','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25234519','lexi-content-ref-11528234','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzed: No dosage adjustment likely to be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment likely to be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment likely to be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988861"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Mild impairment (Child-Pugh class A): 200 mg twice daily (oral solution is recommended).</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Moderate to severe impairment (Child-Pugh class B or C): Use is contraindicated (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F128715"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Rates of adverse reactions were defined during combination therapy with other antiretrovirals.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (adults: ≤13%; infants, children, &amp; adolescents: 1%), fatigue (≤12%), malaise (≤12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (7% to 19%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Abnormal dreams (≤10%), sleep disorder (≤10%), chills (≤9%), migraine (≤7%), depression (6%), dizziness (6%), anxiety (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (5% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypertriglyceridemia (grades 3/4: 2% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea and vomiting (9% to 10%), diarrhea (7%), abdominal pain (≤6%), gastritis (≤6%), gastrointestinal signs and symptoms (≤6%), increased serum amylase (grades 3/4: 2% to 4%), vomiting (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Neutropenia (grades 3/4: 2% to 5%), thrombocytopenia (grades 3/4: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (grades 3/4: 6%), increased serum aspartate aminotransferase (grades 3/4: 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Drug-induced hypersensitivity (9%), hypersensitivity reaction (including anaphylaxis and multiorgan failure; 8%; excluding subjects carrying the HLA-B*5701 allele: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Increased creatine phosphokinase (grades 3/4: 7% to 8%), musculoskeletal pain (5% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: ENT infection (5%), viral respiratory tract infection (5%), bronchitis (4%), pneumonia (infants, children, &amp; adolescents: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (≤9%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased gamma-glutamyl transferase</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Pancreatitis</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Anemia, autoimmune disease, erythema multiforme, Graves disease, Guillain-Barre syndrome, hepatomegaly, hyperglycemia, immune reconstitution syndrome, lactic acidosis, leukopenia, lipotrophy, liver steatosis, myocardial infarction, pain, polymyositis, redistribution of body fat, renal function abnormality, Stevens-Johnson syndrome, toxic epidermal necrolysis</p></div>
<div class="block coi drugH1Div" id="F128728"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Hypersensitivity to abacavir or any component of the formulation; patients who are positive for the HLA-B*5701 allele; moderate to severe hepatic impairment </p></div>
<div class="block war drugH1Div" id="F128712"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: <b>[US Boxed Warning]: Serious and sometimes fatal hypersensitivity reactions have occurred. Patients who carry the HLA-B*5701 allele are at a higher risk for a hypersensitivity reaction to abacavir, although hypersensitivity reactions have occurred in patients who do not carry the HLA-B*5701 allele. All patients should be screened for the HLA-B*5701 allele prior to initiating or reinitiation of therapy unless patients have had a previously documented HLA-B*5701 allele assessment. Discontinue abacavir if a hypersensitivity reaction is suspected. Abacavir is contraindicated in patients who have the HLA-B*5701 allele or in patients with a prior hypersensitivity reaction to abacavir. Reintroduction of any abacavir-containing product can result in life-threatening or fatal hypersensitivity reactions, even in patients who have no history of hypersensitivity to abacavir therapy. Such reactions can occur within hours.</b> An allergy to abacavir should be documented in the medical record of allele-positive patients. Reactions usually occur within 9 days of starting abacavir; ~90% occur within 6 weeks, although these reactions may occur at any time during therapy (HHS [adult] 2019). These reactions usually include signs or symptoms from two or more of the following: Fever, skin rash, constitutional symptoms (malaise, fatigue, aches), respiratory symptoms (eg, pharyngitis, dyspnea, cough), and GI symptoms (eg, abdominal pain, diarrhea, nausea, vomiting). Other signs and symptoms include lethargy, headache, myalgia, edema, abnormal chest x-ray findings, arthralgia and paresthesia. Anaphylaxis, liver failure, renal failure, hypotension, adult respiratory distress syndrome, respiratory failure, myolysis, and death have occurred in association with hypersensitivity reactions. Physical findings (lymphadenopathy, mucous membrane lesions, and rash [maculopapular, urticarial or variable]) may occur. Erythema multiforme has also been reported. Laboratory abnormalities (eg, elevated liver function tests, elevated creatine phosphokinase, elevated creatinine, and lymphopenia) may occur. Abacavir should be permanently discontinued if hypersensitivity cannot be ruled out, even when other diagnoses are possible and regardless of HLA-B*5701 status. Abacavir SHOULD NOT be restarted because more severe symptoms may occur within hours, including LIFE-THREATENING HYPOTENSION AND DEATH. If abacavir is restarted following an interruption in therapy not associated with symptoms of a hypersensitivity reaction, carefully evaluate the patient for previously unsuspected symptoms of hypersensitivity. Do not restart if hypersensitivity is suspected or cannot be ruled out regardless of HLA-B*5701 status. If abacavir is restarted, continually monitor for symptoms of a hypersensitivity reaction. Make the patient aware that reintroduction should only take place if medical care is readily accessible.</p>
<p style="text-indent:-2em;margin-left:4em;">• Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves disease, polymyositis, Guillain-Barré syndrome) later in therapy; further evaluation and treatment may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lactic acidosis/hepatomegaly: Lactic acidosis and severe hepatomegaly with steatosis have been reported with nucleoside analogues, including fatal cases; use with caution in patients with risk factors for liver disease (risk may be increased with female gender or obesity) and suspend treatment in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or hepatotoxicity (transaminase elevation may/may not accompany hepatomegaly and steatosis).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Coronary heart disease: Use has been associated with an increased risk of MI in some cohort studies (Elion 2018; HHS [adult] 2019). Consider using with caution in patients with risks for coronary heart disease and minimizing modifiable risk factors (eg, hypertension, hyperlipidemia, diabetes mellitus, smoking) prior to use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution and adjust dosage in patients with mild hepatic impairment (contraindicated in moderate to severe impairment).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007).</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sorbitol: Oral solution contains sorbitol. Use oral solution with caution in patients who are fructose intolerant; may experience abdominal discomfort and/or diarrhea with administration of the oral solution.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878305"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">May cause mild hyperglycemia; more common in pediatric patients. Abacavir oral solution contains sorbitol, which has been shown to decrease exposure of concurrently administered lamivudine solution in adults (Adkison 2018). Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults, including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F128722"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ziagen: 20 mg/mL (240 mL) [contains methylparaben, propylene glycol, propylparaben, saccharin sodium; strawberry-banana flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg/mL (15 mL [DSC], 240 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ziagen: 300 mg [DSC] [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 300 mg</p></div>
<div class="block geq drugH1Div" id="F128708"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F128731"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Abacavir Sulfate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/mL (per mL): $0.65</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Ziagen Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/mL (per mL): $0.73</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Abacavir Sulfate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $2.98 - $10.05</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52865510"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ziagen: 20 mg/mL (240 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ziagen: 300 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 300 mg</p></div>
<div class="block admp drugH1Div" id="F52612165"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May be administered without regard to food.</p></div>
<div class="block adm drugH1Div" id="F128725"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">May be administered with or without food.</p></div>
<div class="block hazard drugH1Div" id="F49104340"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 2]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>
<p style="text-indent:0em;margin-top:2em;">NIOSH recommends single gloving for administration of intact tablets or capsules. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>
<div class="block sts drugH1Div" id="F128744"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F). Oral solution may be refrigerated; do not freeze.</p></div>
<div class="block meg drugH1Div" id="F7874271"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2020%2F020977s035%2C020978s038lbl.pdf%23page%3D27&amp;token=tQCO0SzY%2BiWpa7DnYK1OEK8itaTPbyZzhEAIcEz8C9IcELZz41tBWPyPKlhxAYlZWEpVxVf%2FZG3%2BzSmnjevFcRyhc7PKT%2FOkkLoaOY3K1Aq%2Bzvazo4FYGY9GRTfmpknV&amp;TOPIC_ID=13176" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020977s035,020978s038lbl.pdf#page=27</a>, must be dispensed with this medication. A Warning Card (summarizing symptoms of hypersensitivity), which is available with the product information, must also be dispensed with this medication for each new outpatient prescription and refill.</p></div>
<div class="block usep drugH1Div" id="F53565171"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of HIV-1 infection in combination with other antiretroviral agents (FDA approved in ages ≥3 months and adults); <b>Note:</b> HIV regimens consisting of three active antiretroviral agents from at least two classes are recommended.</p></div>
<div class="block cyt drugH1Div" id="F13298624"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of BCRP/ABCG2; <b>Inhibits</b> MRP2</p></div>
<div class="block dri drugH1Div" id="F128716"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Betibeglogene Autotemcel: Antiretroviral Agents may diminish the therapeutic effect of Betibeglogene Autotemcel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabozantinib: MRP2 Inhibitors may increase the serum concentration of Cabozantinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Agents that Undergo Intracellular Phosphorylation may diminish the therapeutic effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elivaldogene Autotemcel: Antiretroviral Agents may diminish the therapeutic effect of Elivaldogene Autotemcel.  Management: Avoid use of antiretroviral medications for at least one month, or for the amount of time required for elimination of the retroviral medication, prior to stem cell mobilization and until the all apheresis cycles are finished<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomethadone: May diminish the therapeutic effect of Abacavir. Abacavir may decrease the serum concentration of Levomethadone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovotibeglogene Autotemcel: Antiretroviral Agents may diminish the therapeutic effect of Lovotibeglogene Autotemcel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: May diminish the therapeutic effect of Abacavir. Abacavir may decrease the serum concentration of Methadone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orlistat: May decrease the serum concentration of Antiretroviral Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Riociguat: Abacavir may increase the serum concentration of Riociguat. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49057008"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Contraception is not required to initiate or continue antiretroviral therapy.</p>
<p style="text-indent:0em;margin-top:2em;">The Health and Human Services (HHS) perinatal HIV guidelines consider abacavir a preferred nucleoside reverse transcriptase inhibitor for patients with HIV infection who are not yet pregnant but are trying to conceive.</p>
<p style="text-indent:0em;margin-top:2em;">Maximum viral suppression sustained below the limits of detection prior to conception is recommended for all persons with HIV who are planning a pregnancy. Optimization of the health of the person who will become pregnant is recommended. Selection of or changes to a specific antiretroviral regimen prior to pregnancy should be done as part of a shared decision-making process. In most cases, recommendations from the HHS perinatal HIV guidelines (based on data obtained from cisgender women) can be applied to transgender and gender diverse people assigned female sex at birth.</p>
<p style="text-indent:0em;margin-top:2em;">Health care providers caring for couples planning a pregnancy when one or both partners are diagnosed with HIV may contact the National Perinatal HIV Hotline (1-888-448-8765) for clinical consultation (HHS [perinatal] 2023).</p></div>
<div class="block pri drugH1Div" id="F128732"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Abacavir has a high level of transfer across the human placenta.</p>
<p style="text-indent:0em;margin-top:2em;">No increased risk of overall teratogenic effects has been observed following first trimester exposure according to data collected by the antiretroviral pregnancy registry. Maternal antiretroviral therapy (ART) may be associated with adverse pregnancy outcomes including preterm birth, low birth weight, and small for gestational age infants. Actual risks may be influenced by maternal factors, such as disease severity, gestational age at initiation of therapy, and specific ART regimen, therefore close fetal monitoring is recommended. Because there is clear benefit to appropriate treatment, maternal ART should not be withheld due to concerns for adverse neonatal outcomes. Long-term follow-up is recommended for all infants exposed to antiretroviral medications; children not diagnosed with HIV but who were exposed to ART in utero or as a neonate and develop significant organ system abnormalities of unknown etiology (particularly of the CNS or heart) should be evaluated for potential metabolic dysfunction.</p>
<p style="text-indent:0em;margin-top:2em;">HLA-B*5701 allele status should be evaluated and documented as negative prior to use; abacavir is contraindicated in all patients who are positive for the HLA-B*5701 allele, including patients who are pregnant.</p>
<p style="text-indent:0em;margin-top:2em;">The Health and Human Services (HHS) perinatal HIV guidelines consider abacavir a preferred nucleoside reverse transcriptase inhibitor (NRTI) for pregnant patients with HIV who are antiretroviral naive, who have had ART therapy in the past but are restarting, or who require a new ART regimen (due to poor tolerance or poor virologic response of current regimen). In addition, patients who become pregnant while taking abacavir may continue if viral suppression is effective and the regimen is well tolerated.</p>
<p style="text-indent:0em;margin-top:2em;">The HHS perinatal HIV guidelines consider abacavir in combination with lamivudine to be a preferred NRTI backbone for initial therapy in antiretroviral-naive pregnant patients. This backbone is not recommended with atazanavir/ritonavir or efavirenz if pretreatment HIV RNA is &gt;100,000 copies/mL. In addition, the HHS perinatal HIV guidelines consider abacavir in combination with lamivudine and dolutegravir to be a preferred integrase strand transfer inhibitor regimen for initial therapy in antiretroviral-naive patients who are pregnant.</p>
<p style="text-indent:0em;margin-top:2em;">Abacavir is not a preferred option for empiric treatment when acute HIV infection is diagnosed during pregnancy and is not recommended unless the patient is known to be negative for the HLA-B*5701 allele.</p>
<p style="text-indent:0em;margin-top:2em;">The pharmacokinetics of abacavir are not significantly changed by pregnancy, and dose adjustment is not needed for patients who are pregnant.</p>
<p style="text-indent:0em;margin-top:2em;">ART is recommended for all pregnant people with HIV to maximize their health, maintain the viral load below the limit of detection, and reduce the risk of perinatal transmission. Selection of or changes to a specific antiretroviral regimen during pregnancy should be done as part of a shared decision-making process. Patients on fully suppressive regimens prior to pregnancy generally may continue the same regimen considering known pregnancy outcomes and pharmacokinetic data. Monitoring of patients who are pregnant is more frequent than in patients who are not pregnant. ART initiated during pregnancy can be modified after delivery. In most cases, recommendations from the HHS perinatal HIV guidelines (based on data obtained from cisgender women) can be applied to transgender and gender diverse people assigned female sex at birth.</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to ART is ongoing. Health care providers should enroll all patients exposed to antiretroviral medications during pregnancy in the Antiretroviral Pregnancy Registry (1-800-258-4263). Enrollment should be done as early in pregnancy as possible.</p>
<p style="text-indent:0em;margin-top:2em;">Health care providers caring for pregnant patients with HIV infection and their infants may contact the National Perinatal HIV Hotline (1-888-448-8765) for clinical consultation (HHS [perinatal] 2023).</p></div>
<div class="block mopp drugH1Div" id="F53565170"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">HIV: General recommendations: Management of HIV infection requires extensive monitoring; refer to current guidelines (<a href="/external-redirect?target_url=https%3A%2F%2Fclinicalinfo.hiv.gov%2Fen%2Fguidelines&amp;token=nbsXe3i4qfUea5RCPRHtOXmm4jIHQPk10%2Bpt6G4BSzQwKJFM0Nvf8hDv6AkFR6Vg&amp;TOPIC_ID=13176" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines</a>) for additional guidance. Antiretroviral (ARV) drug-resistance testing is recommended before initiation of therapy in treatment-naive patients and before changing regimens in patients for whom treatment has failed. After initiation of or change in ARV therapy regimen, pediatric patients should be evaluated for clinical adverse effects and treatment adherence at 1 to 2 weeks, and laboratory testing for drug toxicity should occur at 2 to 4 weeks; monitor for therapy adherence, effectiveness, and toxicities every 3 to 4 months.</p>
<p style="text-indent:-2em;margin-left:2em;">Drug-specific monitoring: Frequency may vary based on several factors including age, concomitant therapy, and clinical response; refer to current guidelines for additional information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>HLA-B*5701</i> genotype status prior to initiating therapy or resuming therapy in patients of unknown <i>HLA-B*5701</i> status (including patients previously tolerating therapy); signs and symptoms of hypersensitivity reaction (in all patients, but especially in those untested for the <i>HLA-B*5701</i> allele).</p>
<p style="text-indent:-2em;margin-left:2em;">Serum electrolytes (including anion gap), lipid profiles, hepatic function tests (baseline and periodically with therapy or if clinical presentation indicates need); serum lactate, serum amylase (if clinical presentation indicates need).</p></div>
<div class="block pha drugH1Div" id="F128711"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Nucleoside reverse transcriptase inhibitor. Abacavir is a guanosine analogue which is phosphorylated to carbovir triphosphate which interferes with HIV viral RNA-dependent DNA polymerase resulting in inhibition of viral replication.</p></div>
<div class="block phk drugH1Div" id="F128727"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid and extensive absorption.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 0.86 ± 0.15 L/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">CSF to plasma AUC ratio: 27% to 33%.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 50%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via alcohol dehydrogenase and glucuronyl transferase to inactive carboxylate and glucuronide metabolites; not significantly metabolized by cytochrome P450 enzymes; intracellulary metabolized to carbovir triphosphate.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Tablet: 83%; Solution and tablet provide comparable AUCs.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination (serum):</p>
<p style="text-indent:-2em;margin-left:4em;">Term neonates (PNA 6 to 15 days): Median: 3.93 hours; range: 2.47 to 6.35 hours (Bekker 2021).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥3 months, Children, and Adolescents ≤13 years: 1 to 1.5 hours (Hughes 1999; Kline 1999).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 1.54 ± 0.63 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic impairment (mild): Increases half-life by 58%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life, intracellular: 12 to 26 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak:</p>
<p style="text-indent:-2em;margin-left:4em;">Term neonates (PNA 6 to 15 days): Median: 2 hours; range: 1 to 4 hours (Bekker 2021).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥3 months, Children, and Adolescents ≤13 years: Within 1.5 hours (Hughes 1999).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 0.7 to 1.7 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine: ~83% (1.2% as unchanged drug, 30% as 5'-carboxylic acid metabolite, 36% as the glucuronide, and 15% as other metabolites); feces (16% total dose).</p>
<p style="text-indent:-2em;margin-left:2em;">Clearance (apparent): Single dose 8 mg/kg (Hughes 1999):</p>
<p style="text-indent:-2em;margin-left:4em;">Pediatric patients ≥3 months to ≤13 years: 17.84 mL/minute/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 10.14 mL/minute/kg.</p></div>
<div class="block phksp drugH1Div" id="F51219048"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: In mild hepatic impairment (Child-Pugh score 5 to 6), AUC increased 89%.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F128735"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Filabac | Panka | Plusabcir | Zepril | Ziagenavir</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Ziagen</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Ziagen</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Ziagen</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Abac | Abacavir</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Ziagen</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Ziagenavir</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Ziagen</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">A bec | Abac | Ziagen</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Abacavir | Bavirac | Ziagen</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ziagen</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Abacar | Abacavir | Abamat | Abamune | Ziagen</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Ziagen</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Abacavir accord | Abacavir Hexal | Ziagen</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Abacavir | Ziagen</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Ziagen</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Abacavir accord | Abacavir tarbis | Ziagen</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Abacavir sulphate</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Abacavir accord | Ziagen</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Abacavir arrow | Abacavir mylan | Abacavir sandoz | Ziagen</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Abacavir | Ziagen</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Ziagen</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Ziagen</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Ziagen</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Ziagen</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">A bec | Abamune | Abavir | Virol</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Ziagen</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Ziagen</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Ziagen</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Abac | Abacavir | Abamune | Ziagen</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ziagen</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Ziagen</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Abamune</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Ziagen</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Ziagen</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Ziagen</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Ziagen</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Aurocain | Idefirin | Neolintra | Sygalli | Vurtas | Ziagenavir</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Abacavex | Ziagen</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Abacavir | Avobac</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Abacavir | Abacavir accord | Ziagen</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Ziagen</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Ziagen</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Abacavir | Abacavir Prp | Abacavir sulfato | Ziagen</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Ziagen</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Abacavir | Ziagen</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Abacavir Farmoz | Abacavir Generis | Abacavir mylan | Abacavir sandoz | Ziagen</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Zepril</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Ziagen</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Abacavir aurobindo | Ziagen</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Abacavir | Abacavir abc | Abacavir canon | Olitid | Ziagen</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Ziagen</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Abacavir accord | Ziagen</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Ziagen</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Ziagen</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Ziagen</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Abacavir sulfate atlanta medicare | Ziagenavir</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Abacavir mylan</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Ziagen</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Ziagen</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Abacavir sulfat | Abacaviri sulfas</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Abacavir sulphate</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Filabac | Finecil</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ziagen</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Abacavir | Adco abacavir | Aspen Abacavir | Auro Abacavir | Bacamune 300 | Bavir | Cipla abacavir | Hetacav | Kavimun paed | Sonke abacavir | Ziagen</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Abac | Abacavir sulphate | Ziagen</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Abac | Abacavir sulphate | Ziagen</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29150845">
<a name="29150845"></a>Adkison K, Wolstenholme A, Lou Y, et al. Effect of sorbitol on the pharmacokinetic profile of lamivudine oral solution in adults: an open-label, randomized study. <i>Clin Pharmacol Ther</i>. 2018;103(3):402-408. doi:10.1002/cpt.943<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abacavir-pediatric-drug-information/abstract-text/29150845/pubmed" id="29150845" target="_blank">29150845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abacavir-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34883066">
<a name="34883066"></a>Bekker A, Capparelli EV, Violari A, et al; IMPAACT P1106 team. Abacavir dosing in neonates from birth to 3 months of life: a population pharmacokinetic modelling and simulation study. <i>Lancet HIV</i>. 2022;9(1):e24-e31. doi:10.1016/S2352-3018(21)00266-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abacavir-pediatric-drug-information/abstract-text/34883066/pubmed" id="34883066" target="_blank">34883066</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32697327">
<a name="32697327"></a>Bekker A, Decloedt EH, Slade G, Cotton MF, Rabie H, Cressey TR. Single dose abacavir pharmacokinetics and safety in neonates exposed to human immunodeficiency virus (HIV). <i>Clin Infect Dis</i>. 2021;72(11):2032-2034. doi:10.1093/cid/ciaa1026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abacavir-pediatric-drug-information/abstract-text/32697327/pubmed" id="32697327" target="_blank">32697327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. Available at <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29419568">
<a name="29419568"></a>Elion RA, Althoff KN, Zhang J, et al; North American AIDS Cohort Collaboration on Research and Design of IeDEA. Recent abacavir use increases risk of type 1 and type 2 myocardial infarctions among adults with HIV. <i>J Acquir Immune Defic Syndr</i>. 2018;78(1):62-72. doi: 10.1097/QAI.0000000000001642.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abacavir-pediatric-drug-information/abstract-text/29419568/pubmed" id="29419568" target="_blank">29419568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9585869">
<a name="9585869"></a>Foster RH and Faulds D, “Abacavir,” <i>Drugs,</i> 1998, 55(5):729-36.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abacavir-pediatric-drug-information/abstract-text/9585869/pubmed" id="9585869" target="_blank">9585869</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27624144">
<a name="27624144"></a>Guillemi SA, Ling SH, Dahlby JS, et al. Effects of a switch from tenofovir- to abacavir-based antiretroviral therapy, with or without atazanavir, on renal function. <i>J Int AIDS Soc.</i> 2016;19(1):20995. doi:10.7448/IAS.19.1.20995<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abacavir-pediatric-drug-information/abstract-text/27624144/pubmed" id="27624144" target="_blank">27624144</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Havlir.1">
<a name="Havlir.1"></a>Havlir DV and Lange JM, “New Antiretrovirals and New Combinations,” <i>AIDS</i>, 1998, 12(Suppl A):165-74.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11943262">
<a name="11943262"></a>Hetherington S, Hughes AR, Mosteller M, et al, "Genetic Variations in HLA-B Region and Hypersensitivity Reactions to Abacavir," <i>Lancet</i>, 2002, 359(9312):1121-2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abacavir-pediatric-drug-information/abstract-text/11943262/pubmed" id="11943262" target="_blank">11943262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abacavir-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abacavir-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11528234">
<a name="11528234"></a>Izzedine H, Launay-Vacher V, Aymard G, Legrand M, Deray G. Pharmacokinetics of abacavir in HIV-1-infected patients with impaired renal function. <i>Nephron</i>. 2001;89(1):62-67. doi:10.1159/000046045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abacavir-pediatric-drug-information/abstract-text/11528234/pubmed" id="11528234" target="_blank">11528234</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10049275">
<a name="10049275"></a>Hughes W, McDowell JA, Shenep J, et al. Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children. <i>Antimicrob Agents Chemother</i>. 1999;43(3):609-615. doi:10.1128/AAC.43.3.609<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abacavir-pediatric-drug-information/abstract-text/10049275/pubmed" id="10049275" target="_blank">10049275</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10103339">
<a name="10103339"></a>Kline MW, Blanchard S, Fletcher CV, et al, “A Phase I Study of Abacavir (1592U89) Alone and in Combination With Other Antiretroviral Agents in Infants and Children With Human Immunodeficiency Virus Infection,” <i>Pediatrics</i>, 1999, 103(4):e47. Available at http://www.pediatrics.org/cgi/content/full/103/4/e47
                     <span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abacavir-pediatric-drug-information/abstract-text/10103339/pubmed" id="10103339" target="_blank">10103339</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23917901">
<a name="23917901"></a>Kuhar DT, Henderson DK, Struble KA, et al, "Updated US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Postexposure Prophylaxis," <i>Infect Control Hosp Epidemiol</i>, 2013, 34(9): 875-92.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abacavir-pediatric-drug-information/abstract-text/23917901/pubmed" id="23917901" target="_blank">23917901</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17317695">
<a name="17317695"></a>Lucas A, Nolan D, and Mallal S, “HLA-B*5701 Screening for Susceptibility to Abacavir Hypersensitivity,” <i>J Antimicrob Chemother</i>, 2007, 59(4):591-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abacavir-pediatric-drug-information/abstract-text/17317695/pubmed" id="17317695" target="_blank">17317695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25234519">
<a name="25234519"></a>Lucas GM, Ross MJ, Stock PG, et al; HIV Medicine Association of the Infectious Diseases Society of America. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(9):e96-138. doi:10.1093/cid/ciu617<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abacavir-pediatric-drug-information/abstract-text/25234519/pubmed" id="25234519" target="_blank">25234519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abacavir-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11888582">
<a name="11888582"></a>Mallal S, Nolan D, Witt C, et al, “Association Between Presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and Hypersensitivity to HIV-1 Reverse-Transcriptase Inhibitor Abacavir,” <i>Lancet</i>, 2002, 359:727-32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abacavir-pediatric-drug-information/abstract-text/11888582/pubmed" id="11888582" target="_blank">11888582</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11888583">
<a name="11888583"></a>Paediatric European Network for Treatment of AIDS (PENTA), "Comparison of Dual Nucleoside-Analogue Reverse-Transcriptase Inhibitor Regimens With and Without Nelfinavir in Children with HIV-1 Who Have Not Previously Been Treated: The PENTA 5 Randomised Trial," <i>Lancet</i>, 2002, 359(9308):733-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abacavir-pediatric-drug-information/abstract-text/11888583/pubmed" id="11888583" target="_blank">11888583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Peyriere.1">
<a name="Peyriere.1"></a>Peyriére H, Nicolas J, Siffert M, et al, "Hypersensitivity Related to Abacavir in Two Members of a Family," <i>Ann Pharmacother</i>, 2001, 35(10):1291-2.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-PHAC.1">
<a name="PHAC.1"></a>Public Health Agency of Canada (PHAC), Canadian Guidelines on Sexually Transmitted Infection. Last modified December 2013. Available at <a href="https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines.html" target="_blank">https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines.html</a>. Accessed December 30, 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9675636">
<a name="9675636"></a>Schmit JC and Weber B, “Recent Advances in Antiretroviral Therapy and HIV Infection Monitoring,” <i>Intervirology</i>, 1997, 40(5-6):304-21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abacavir-pediatric-drug-information/abstract-text/9675636/pubmed" id="9675636" target="_blank">9675636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abacavir-pediatric-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abacavir-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9854567">
<a name="9854567"></a>“Three New Drugs for HIV Infection,” <i>Med Lett Drugs Ther</i>, 1998, 40(1041):114-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abacavir-pediatric-drug-information/abstract-text/9854567/pubmed" id="9854567" target="_blank">9854567</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf</a>. Updated December 18, 2019. Accessed December 18, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2">
<a name="HHS.2"></a>US Department of Health and Human Services (HHS) Panel on Antiretroviral Therapy and Medical Management of Children living with HIV. Guidelines for the use of antiretroviral agents in pediatric HIV infection. <a href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new</a>. Updated April 11, 2023. Accessed May 26, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.3">
<a name="HHS.3"></a>US Department of Health and Human Services (HHS) Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States. <a href="https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new</a>. Updated December 30, 2021. Accessed January 3, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.4">
<a name="HHS.4"></a>US Department of Health and Human Services (HHS) Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States. <a href="https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new</a>. Updated January 31, 2023. Accessed February 23, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9708401">
<a name="9708401"></a>Weverling GJ, Lange JM, Jurriaans S, et al. Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy. <i>AIDS</i>, 1998;12(11):F117-122.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abacavir-pediatric-drug-information/abstract-text/9708401/pubmed" id="9708401" target="_blank">9708401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18479171">
<a name="18479171"></a>Yuen GJ, Weller S, Pakes GE. A review of the pharmacokinetics of abacavir. <i>Clin Pharmacokinet</i>. 2008;47(6):351-371. doi:10.2165/00003088-200847060-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abacavir-pediatric-drug-information/abstract-text/18479171/pubmed" id="18479171" target="_blank">18479171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abacavir-pediatric-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ziagen.1">
<a name="Ziagen.1"></a>Ziagen (abacavir sulfate) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; November 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ZiagenCAN.1">
<a name="ZiagenCAN.1"></a>Ziagen (abacavir sulfate) [product monograph]. Laval, Quebec, Canada: ViiV Healthcare ULC; January 2021.</div>
</li></ol></div><div id="topicVersionRevision">Topic 13176 Version 281.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
